Brief: Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam For Tsc-Related Epilepsy
04/08/2025 12:59
Aug 4 (Reuters) - Cassava Sciences Inc SAVA.O: CASSAVA SCIENCES REPORTS POSITIVE PRECLINICAL STUDY EVALUATING SIMUFILAM FOR TSC-RELATED EPILEPSY CASSAVA SCIENCES INC - CLINICAL STUDY FOR SIMUFILAM IN TSC EPILEPSY EXPECTED IN H1 2026 Source text: ID:nGNXbPpxDk Further company coverage: SAVA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Filana Therapeutics
See all newsCassava Sciences says US DOJ has closed investigation into company (updated)
Cassava Sciences rises after US DOJ closes probe into company
Cassava Sciences says US DOJ has closed investigation into company
Brief: Cassava Announces Agreement To Settle Securities Class Action Litigation
Brief: Cassava Sciences Inc - On Dec 15, FDA Places Full Clinical Hold On Cassava's Trial - SEC Filing